In a resolution dated the 9th of March, 2018, Minister Carmen Castillo Taucher of Chile’s Ministry of Health has announced that there are sufficient public health reasons to support a compulsory license on medicines for the hepatitis C virus (HCV),… Continue Reading
This is an update to a 2007 report regarding a district court decision in the Innogenetics v. Abbott case here, regarding Abbott’s infringement of Innogenetics’s patents for HCV genotyping. The previous blog discusses the ruling at the district court level… Continue Reading
There is a specialized web page on delinkage here: http://delinkage.org De-linkage can be defined in the negative, by saying that the R&D funding should not be tied to the price of the product. Progressive de-linkage means that governments implement reforms… Continue Reading
KEI Briefing Note 2018:1. Bayh-Dole Obligations to Disclose Federal Funding Government oversight of under-reporting U.S. federal rights in patents. 1994. June 15, 1994, Inspector General Report to HHS on the under-reporting of federal funding of inventions at the Scripps Research… Continue Reading
World Health Assembly, May 2001 Statements May 21, 2001. Health GAP Report on the 54th World Health Assembly. May 18, 2001. CPT/Essential Action Comments on the World Health Assembly. May 17, 2001. HealthGAP Coalition Release on the World Health Assembly.… Continue Reading
KEI page on Research and Development Cost Transparency Legislation EB142: KEI statement on Addressing the global shortage of, and access to, medicines and vaccines, January 24th, 2018 Expert Panel charts a road map for WHO’s engagement on transparency and R&D,… Continue Reading
On Tuesday, 27 February 2018, the representative of the Republic of South Africa delivered the following statement at the World Trade Organization’s TRIPS Council; South Africa delivered this statement under the agenda item on IP and the Public Interest: Regulatory… Continue Reading
KEI page on the World Trade Organization’s (WTO) Trade Policy Reviews All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the “Trade Policy Review Body which is actually… Continue Reading
Read first: Statutory authority for compulsory licenses on patents in the United States KEI Workshop: Feb 24, 2017 – U.S. History, Experiences, and Prospects of Compulsory Licensing of Medical Patents. There is a Video of the event here here. Non-voluntary… Continue Reading
The October 2017 meeting of the WTO TRIPS Council witnessed heated discussions on compulsory licensing within the context of IP and the Public Interest. As reported earlier by Knowledge Ecology International, on 31 May 2017, Brazil, China, Fiji, India, and… Continue Reading